<DOC>
	<DOCNO>NCT02505685</DOCNO>
	<brief_summary>The purpose study evaluate use Dynamic PET/CT tool ass disease response anti-cancer therapy Lung Cancer patient .</brief_summary>
	<brief_title>Dynamic PET CT Tool Treatment Efficacy Monitoring Lung Cancer</brief_title>
	<detailed_description>Background : Lung cancer devastate disease response first line therapy 30 % . Evaluating response perform normally CT PET-CT scan 2-3 cycle therapy , thus , lack response evaluate patient treat follow significant amount therapy , inefficient 70 % case . Therefore , urgent need develop tool might predict response therapy early course therapy ; Most valuable first cycle therapy . For reason , investigator aim study evaluate use Dynamic PET-CT tool ass disease response anti-cancer therapy Lung Cancer patient . Objectives : 1 . To assess feasibility baseline Dynamic PET-CT tool assess response anti-cancer therapy Lung Cancer patient . 2 . To predict early response treatment soon 1 cycle therapy dynamic static PET-CT. 3 . To correlate Dynamic PET-CT survival/disease free survival Method : 200 advance lung cancer patient enrol 3 year single institute , single arm study Rabin Medical Center , Beilinson Hospital . Patients evaluated Dynamic PET-CT protocol : initiation therapy , 7-14 day first therapy cycle , 3 month initiation therapy 6 month first therapy cycle . In addition , non-invasive biomarkers routinely measure include protein marker ( CEA- Carcinoembryonic Antigen , CYFRA21- Cytokeratin 19 Fragment , NSE- Neuron Specific Enolase ) assess trial . Disease response evaluate Response Evaluation Criteria In Solid Tumors ( RECIST criterion ) . Additional PET-CT increase radiation dose significantly . The mean estimate radiation dose limit CT chest 14 mSv ( i.e. , 7mSv limited diagnostic CT FDG ( [ 18F ] -fluorodeoxyglucose ) , ) . The dynamic stage add radiation dose 0.3mSv . Of note , significance add radiation dose less importance regard treatment patient aggressive cancer .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Age &gt; 18 year . Lung cancer , stage 4 Patients plan treated systemic anticancer therapy . A define lesion imaging . Able willing sign inform consent form . First line therapy least 6 week previous line therapy Pregnant lactate woman . Anti cancer therapy within last 6 week enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Lung</keyword>
	<keyword>Cancer</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>PET-CT</keyword>
	<keyword>Early detection</keyword>
</DOC>